Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - ASPARTAME DOUBTS

Calorie Control Council Statement: Allegations Against Aspartame Unfounded

 

BY OUR PHARMA  CORRESPONDENT

 1 August, 2005: /PRNewswire/ -- The Calorie Control Council today stated that reports of a preliminary unpublished rat study alleging that aspartame may be related to an increased risk of leukemia and lymphoma in rats are unsupported and totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. Acceptance and reporting of such preliminary findings should be withheld until the research is completed.

The Ramazzini Institute in Bologna, Italy plans to publish a study report in their own publication. Their publication, the "European Journal of Oncology," is not included in the MedLine (National Library of Medicine) database, the world's leading source of scientific literature. Also, the researchers at Ramazzini have not followed the internationally established protocol for evaluation of animal carcinogenicity study findings.

All of the approved low-calorie sweeteners have been determined to be safe by the U.S. Food and Drug Administration and other scientific and regulatory authorities worldwide. Aspartame has been safely consumed for nearly a quarter of a century, and is one of the most thoroughly studied food ingredients, with more than 200 scientific studies confirming its safety. In addition to the FDA, the Joint Expert Committee on Food Additives (JECFA) of the World Health Organization and Food and Agriculture Organization, the Scientific Committee on Food of the European Union and regulatory agencies in 130 countries have reviewed aspartame and found it to be safe for use.

Four long-term carcinogenicity studies on aspartame conducted in accordance with international standards have found no relationship between aspartame and any form of cancer. The studies were submitted to numerous regulatory agencies, such as the FDA, which conducted exhaustive reviews of the data.

Aspartame is composed of two amino acids, aspartic acid and phenylalanine, as the methyl ester. Amino acids are the building blocks of protein. Aspartic acid and phenylalanine are found naturally in protein containing foods, including meats, grains and dairy products. Methyl esters are also found naturally in many foods such as fruits and vegetable and their juices. The body handles the components from aspartame in the same way it handles them when derived from other foods.

When FDA approved aspartame, the FDA Commissioner noted: "Few compounds have withstood such detailed testing and repeated, close scrutiny, and the process through which aspartame has gone should provide the public with additional confidence of its safety."

The Ramazzini researchers' pathology slides have not been peer reviewed. The National Toxicology Program (NTP) has established guidelines for pathology peer review in order to provide scientific consensus that study conclusions are valid. Ramazzini researchers were asked several months ago to subject their findings to the NTP peer review process but have not responded to the request. Additionally, the researchers reportedly have not concluded statistical analyses of their findings.

Previous findings by these researchers at the same institution using a similar protocol have been reviewed by the FDA's Cancer Assessment Committee, which noted that those reported data were "unreliable" due to a "lack of critical details ... and ... questionable histopathological conclusions ...."

Based on the current information from Ramazzini, the European Food Safety Authority (EFSA) (a scientific body charged with providing independent and objective advice on food safety issues in the European Union) stated, "EFSA does not consider it appropriate to suggest any change in consumers' diets relative to aspartame ...." Health Canada has also stated that based on the limited new information available, it is not recommending any dietary changes relating to the use of aspartame.

The American Cancer Society, in addressing previous allegations of a possible link between aspartame and cancer has stated, "Current evidence does not demonstrate any link between aspartame ingestion and increased cancer risk."

"With billions of man-years of safe use, consumers and health professionals can be assured that aspartame is safe for humans. And the rigorous scrutiny and battery of studies to which aspartame has been subjected should provide people with additional confidence in its safety," stated Lyn Nabors, executive vice president of the Calorie Control Council.

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

More funding for Sentinel Breastscan

New drug Provigil can keep you awake: Cephalon

Anti-virals can stem global flu outbreak: Studies

USFDA’s recall overdrive creates panic among drug users

Backjoy - A chair support that helps relieve back pain

Why does mammography lead to pain for some black women?

What after the Atkins diet?

Perrigo recalls infants’ oral drops in US

Diovan approved to treat heart failure in US

British Pharma seeks opinion on industry code

Novartis gets EU nod for Xolair

Eli Lilly to submit ruboxistaurin for diabetic vision loss

Snuppy: The first cloned dog

India bans valdecoxib

UK recalls Lipitor fakes

Drug developers set sight on 'interactome'

Ranbaxy gets US FDA nod for sumatriptan tabs

US FDA approval for Orchid's ceftriaxone vials

Pfizer's Celebrex approved for spondilitis

IVAX gets FDA okay for hydrochlorothiazide caps

Mumbai floods: Pharma sector losses estimated at Rs 1,000 crore

Calorie Control Council Statement: Allegations Against Aspartame Unfounded

European biotech start-ups fail to win late-stage funds

Ranbaxy gets USFDA nod for glimepiride tabs

Experts debate benefits of heart implant in US

US FDA blocks sale of Pharmakon's illegal drugs

Echinacea does not prevent common cold: Study

Afghan’s first generics plant to go on stream by Oct. ‘05

PhRMA seeks voluntary DTC ad code

Barr, Teva get fexofenadine approvals from US FDA

Novartis completes Eon Labs buy

Able Laboratories files bankruptcy suit with US court

Orbus inks supply pact with Docpharma 

Matrix acquires controlling stake in Docpharma

Actavis launches Fosinopril in Netherlands, Sweden &UK; Benazepril in Germany

Insomnia treatment: ROZEREM approved by FDA

Stories below archived on 25 July, 2005

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us